Trial Profile
An Open-label, Single Dose, Multicenter Study to Evaluate the Pharmacokinetics and Safety of 50 mg Oral Buparlisib in Subjects With Moderate and Severe Renal Impairment Compared to Matched Control Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2020
Price :
$35
*
At a glance
- Drugs Buparlisib (Primary)
- Indications Breast cancer; Gastrointestinal stromal tumours; Glioblastoma; Haematological malignancies; Male breast cancer; Malignant melanoma; Non-Hodgkin's lymphoma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis
- 25 Mar 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
- 29 Jan 2015 Planned End Date changed from 1 Nov 2014 to 1 Apr 2014 as per ClinicalTrials.gov record.
- 29 Jan 2015 Planned primary completion date changed from 1 Nov 2014 to 1 Apr 2014 as per ClinicalTrials.gov record.